Invesco
PVLA

Invesco’s Palvella Therapeutics PVLA Stock Holding History

Invesco’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.14M Sell
33,652
-14,875
-31% -$1.81M ﹤0.01% 2221
2026
Q1 		$6.05M Sell
48,527
-5,746
-11% -$599K ﹤0.01% 2102
2025
Q4 		$5.68M Buy
54,273
+5,663
+12% +$483K ﹤0.01% 2187
2025
Q3 		$3.05M Buy
+48,610
New +$2.17M ﹤0.01% 2450
2021
Q4 		– Sell
-18,771
Closed -$7.76M – 4114
2021
Q3 		$7.76M Buy
+18,771
New +$6.54M ﹤0.01% 2148
2021
Q2 		– Sell
-169
Closed -$35K – 4048
2021
Q1 		$35K Buy
169
+33
+24% +$7.21K ﹤0.01% 3843
2020
Q4 		$27K Buy
+136
New +$28.3K ﹤0.01% 3757
2019
Q4 		– Sell
-1,880
Closed -$513K – 3712
2019
Q3 		$513K Buy
+1,880
New +$728K ﹤0.01% 3241
2019
Q1 		– Sell
-160
Closed -$34K – 3846
2018
Q4 		$34K Buy
160
+1
+0.6% +$310 ﹤0.01% 3731
2018
Q3 		$71K Sell
159
-333
-68% -$145K ﹤0.01% 3804
2018
Q2 		$199K Sell
492
-996
-67% -$474K ﹤0.01% 3706
2018
Q1 		$812K Buy
+1,488
New +$921K ﹤0.01% 3120

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Invesco's PVLA Position: Q2 2026 in Review

Invesco reduced its Palvella Therapeutics (PVLA) stake by 31% in Q2 2026, selling an estimated $1.81M and leaving 33,652 shares worth $5.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2221.

Invesco first reported a position in PVLA in Q1 2018 and has held it in 12 quarters since. The position peaked at $7.76M in Q3 2021. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Invesco held 33,652 shares of Palvella Therapeutics worth $5.14M as of Q2 2026.
  • Invesco sold 14,875 Palvella Therapeutics shares in Q2 2026, an estimated $1.81M.
  • Palvella Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2221 holding.
  • Invesco first reported a position in Palvella Therapeutics in Q1 2018 and has held it in 12 quarters since.
  • Invesco's Palvella Therapeutics position peaked at $7.76M in Q3 2021.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.